Share

January 2022; 9 (1) ArticleOpen Access

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients

Case Series

Roseanne Sullivan, Ajay Kilaru, Bernhard Hemmer, Bruce Anthony Campbell Cree, Benjamin M. Greenberg, Uma Kundu, Thomas Hach, Virginia DeLasHeras, Brian J. Ward, Joseph Berger
First published November 30, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001092
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1045

Share

Article Information

vol. 9 no. 1 e1092
DOI: 
https://doi.org/10.1212/NXI.0000000000001092
PubMed: 
34848501
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received March 24, 2021
  • Accepted in final form August 18, 2021
  • First Published November 30, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Roseanne Sullivan, PharmD,
    2. Ajay Kilaru, MBBS (ajay.kilaru{at}novartis.com),
    3. Bernhard Hemmer, MD, PhD (hemmer{at}tum.de),
    4. Bruce Anthony Campbell Cree, MD, PhD (bruce.cree{at}ucsf.edu),
    5. Benjamin M. Greenberg, MD (benjamin.greenberg{at}utsouthwestern.edu),
    6. Uma Kundu, MPharm (uma.kundu{at}novartis.com),
    7. Thomas Hach, MD (thomas.hach{at}novartis.com),
    8. Virginia DeLasHeras, MD (virginia.delasheras{at}novartis.com),
    9. Brian J. Ward, MD, PhD (brian.ward{at}mcgill.ca) and
    10. Joseph Berger, MD (joseph.berger{at}uphs.upenn.edu)
  1. Roseanne Sullivan, PharmD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Novartis Pharmaceutical Company Sr. Medical Safety Lead 4 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ajay Kilaru, MBBS (ajay.kilaru{at}novartis.com),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Bernhard Hemmer, MD, PhD (hemmer{at}tum.de),
    4. Scientific Advisory Boards:

    1. Advisory Boards for Novartis, he has served as DMSC member for AllergyCare, TG Therapeutics and Polpharma Biologics

    Gifts:

    1. Me or my institution have received speaker honoraria from Desitin

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial board member of Jama Neurology, Experimental Neurology and Multiple sclerosis Journal

    Patents:

    1. I hold part of two patents; one for the detection of antibodies and T cells against KIR4.1 in a subpopulati on of MS patients and one for genetic determinants of neutralizing antibodies to interferon β

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Regeneron - not related

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Bruce Anthony Campbell Cree, MD, PhD (bruce.cree{at}ucsf.edu),
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Novartis, Sanofi, TG Therapeutics and Therein

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Genentech

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Benjamin M. Greenberg, MD (benjamin.greenberg{at}utsouthwestern.edu),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Greenberg has filed patents on the use of antibody biology in multiple sclerosis

    Publishing Royalties:

    1. Transverse Myelitis, UpToDate

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novartis, Alexion, EMD Serono, Genentech, Horizon Therapeutics, Rubin Anders

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. CLENE Nanomedicine, Anokion

    Research Support, Government Entities:

    1. NIH RO1 NS071463, Co-investigator 2012-14, PCORI, PI, 2013-2020

    Research Support, Academic Entities:

    1. Unviersity of Texas Southwestern

    Research Support, Foundations and Societies:

    1. Guthy Jackson Foundation, Siegel Rare Neuroimmune Association, National MS Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Expert witness in patent litigation involving Mylan

  6. Uma Kundu, MPharm (uma.kundu{at}novartis.com),
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. 1. Employee of Novartis Healthcare Pvt. Ltd, Expert Scientific Writer, 11 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Thomas Hach, MD (thomas.hach{at}novartis.com),
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Employed by Novartis Pharma AG, Basel.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Stock of Novartis Pharma AG

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Virginia DeLasHeras, MD (virginia.delasheras{at}novartis.com),
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am a Novartis employee. Global medical Director of Neuroscience. 2 years.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. I am a Novartis employee for more than 2 years Stock/Stock Options, Medical Equipment & Materials: I am a Novartis employee for more than 2 years

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Brian J. Ward, MD, PhD (brian.ward{at}mcgill.ca) and
    10. Scientific Advisory Boards:

    1. Serve on expert committee for Novartis to review infectious disease complications of disease-modifying therapies

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Occasional speaker fees for talks related to infectious diseases and vaccine use in people taking of disease-modifying therapies and vaccine use

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Serve as medical officer for Medicago Inc since 2009, a biotechnology company making vaccines and monoclonal antibodies in plants (no commercial products)

    Consultancies:

    1. Serve as an ad hoc consultant for Novartis to address questions from practitioners related to infectious disease complications of disease-modifying therapies

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Joseph Berger, MD (joseph.berger{at}uphs.upenn.edu)
    11. Scientific Advisory Boards:

    1. Dr. Berger serves as a consultant and/or on the PML adjudication committees of Novartis and Takeda/Millennium. He also serves on the Scientific Advisory Board ExcisionBio and Inhibikase. He is chair of the Data Safety Monitoring Board for MAPI.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Berger has received honoraria from Prime Education, AcademicCME, Arcus Medica, Eisenhower Medical Center, River West Meetings, and the MS Foundation for lectures.

    Editorial Boards:

    1. Dr. Berger serves as an editorial board member of the Journal of Neurovirology, Neurology Reviews and MS and Related Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. Portegies P, Berger JR (Editors): HIV/AIDS and the Nervous System. In Vinken PJ, Bruyn G (Editors): Handbook of Clinical Neurology, Volume 85; Elsevier, Amsterdam, 2007. Nath A and Berger JR (Editors): Clinical Neurovirology. Taylor Francis, NY, 2020.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Berger serves as a consultant to Biogen, Celgene/Bristol Myers Squibb, Dr. Reddy, EMD Serono, Genzyme/Sanofi, Merck, Roche/Genentech, Morphic, Encycle, Novartis, and Millennium/Takeda.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Biogen 2) Genentech

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Novartis Pharmaceuticals Corporation (R.S.), East Hanover, NJ; Novartis Pharma AG (A.K., T.H., V.D.), Basel, Switzerland; Department of Neurology, Technical University of Munich, and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Germany; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco, CA; Department of Neurology (B.M.G.), University of Texas Southwestern, Dallas, TX; Novartis Healthcare Pvt. Ltd. (U.K.), Hyderabad, India; Department of Medicine (B.J.W.), Division of Experimental Medicine, Research Institute of the McGill University Health Centre, Montreal, Canada; and Department of Neurology (J.B.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  1. Correspondence
    Dr. Sullivan roseanne.sullivan{at}novartis.com
View Full Text

Article usage

Article usage: November 2021 to February 2023

AbstractFullPdfSource
Nov 20210643Highwire
Dec 202171399292Highwire
Jan 2022191289180Highwire
Feb 20221062180Highwire
Mar 2022442468Highwire
Apr 2022638151Highwire
May 2022628554Highwire
Jun 2022532543Highwire
Jul 2022934028Highwire
Aug 20221121430Highwire
Sep 20221822362Highwire
Oct 2022920732Highwire
Nov 20221119045Highwire
Dec 2022818027Highwire
Jan 20231215526Highwire
Feb 202389924Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me